Lenvatinib suppresses autophagy by inhibiting NRP1 expression in HCC cells; however, although co-treatment with bafilomycin A1 reduces the anti-tumor effect of lenvatinib, silencing the NRP1 gene can also reduce the efficacy of lenvatinib even in the presence of bafilomycin A1. This evidence concerns the gene NRP1 and neoplasm.